Novo Nordisk has reportedly begun U.S. layoffs

[New Nordisk]
hapabapa/iStock Editorial via Getty Images

Novo Nordisk (NVO [https://seekingalpha.com/symbol/NVO]) has started a round of job cuts in the U.S. as the weight loss drugmaker continues its plans to eliminate about 9,000 roles globally under a major restructuring drive, Reuters reported on Wednesday, citing an email and two sources familiar with the matter.

The layoffs began on Tuesday, with affected staff members expected to be notified this week and the next. Job cuts will continue until late next week, impacting several departments, including HR, marketing & sales, clinical development, legal, ethics, and compliance, according to an email schedule.

Soon after assuming office in August, Novo’s (NVO [https://seekingalpha.com/symbol/NVO]) new CEO Mike Doustdar started a company-wide reorganization as the maker of the obesity drug Wegovy [https://www.cnbc.com/2025/10/15/novo-nordisk-begins-round-of-layoffs-in-united-states.html] plays catch-up to its U.S. rival Eli Lilly (LLY [https://seekingalpha.com/symbol/LLY]) in the booming market for weight loss drugs.

Last week, Bloomberg News reported that the company is closing its cell therapy unit as part of the initiative, impacting all 250 employees there. [https://seekingalpha.com/news/4503355-novo-nordisk-closing-cell-therapy-unit]

MORE ON NOVO NORDISK

* Akero: Novo Nordisk Acquisition Puts Focus On Unprecedented MASH Data With EFX [https://seekingalpha.com/article/4829066-akero-novo-nordisk-acquisition-puts-focus-on-unprecedented-mash-data-with-efx]
* Novo Nordisk's Akero Deal: Panic Buy Or Wise Decision? Here's My Take [https://seekingalpha.com/article/4828906-novo-nordisk-akero-deal-panic-buy-or-wise-decision]
* Novo Nordisk to Acquire Akero Therapeutics Inc. [https://seekingalpha.com/article/4828884-novo-nordisk-to-acquire-akero-therapeutics-inc]
* Novo Nordisk boosts Omeros with licensing deal worth up to $2.1B [https://seekingalpha.com/news/4504255-omeros-stock-spikes-novo-licensing-deal]
* Key deals this week: Protagonist Therapeutics, Bristol Myers, Novo Nordisk, Fifth Third Bancorp and more [https://seekingalpha.com/news/4503442-key-deals-this-week-protagonist-therapeutics-bristol-myers-novo-nordisk-fifth-third-bancorp-and-more]